142 Survival outcomes for concurrent chemo-radiotherapy (cCRT) patients in stage III lung cancer: Real world data from the northern centre for cancer care (NCCC) utilising 2 regimes.
Standard of care for stage-III un-resectable disease is cCRT. NCCC reviewed cCRT practices in 2020, introducing a stage-III MDT to optimise treatment pathways, with the aim of expanding inclusion of patients to reflect real-life local population. A concurrent regime of weekly carboplatin/paclitaxel (carbo/taxol) with 60 –66 Gy/ 2 Gy fractions was introduced for PS0-2 patients, alongside preexisting concurrent Cisplatin/Vinorelbine (Cis/Vin) with 55 Gy hypo-fractionated regime for PS0-1 patients. Adjuvant-durvalumab immunotherapy in appropriate patients was adopted.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Rebecca Pickles, EIeanor Smith, AIexander Stamp, Fiona E Mcdonald, Adam Hassani, Alistair Greystoke Tags: Radiotherapy Source Type: research